NEW YORK, NY / ACCESSWIRE / September 15, 2017 / The Dow Jones Industrial Average closed at a new record high for the third consecutive session on the strength of Boeing and United Technologies, while the other major indexes were dragged down by the retail sector. The Dow Jones gained 0.20 percent to close at a record 22,203.48. The S&P 500 Index declined 0.11 percent to close at 2,495.62, while the Nasdaq Composite Index fell 0.48 percent to close at 6,429.08. The Consumer Prices Index saw an increase of 1.9 percent in August, which topped estimates of an increase of 1.8 percent, according to economists surveyed by Reuters.

"The market continues to hit all-time highs, yet there are a myriad of excuses for it to sell off," said Michael Scanlon, a portfolio manager at Manulife Asset Management. "Until we get to the next earnings season and see a draft of the tax proposal, markets may cool."

RDI Initiates Coverage on:

Aldeyra Therapeutics Inc.
https://rdinvesting.com/news/?ticker=ALDX

Arrowhead Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=ARWR

Aldeyra Therapeutics's stock jumped 71.65% Thursday, to close the day at $10.90. The stock recorded a trading volume of 10,131,532 shares, which was above its three months average volume of 410,006 shares. In the last year Aldeyra Therapeutics's shares have traded in a range of 3.80 - 11.05. The share price has gained 186.84% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $4.62 is below its 200-day moving average of $4.72. Shares of Aldeyra Therapeutics have gained approximately 101.87 percent year-to-date.

Access RDI's Aldeyra Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ALDX

On Thursday, shares in Arrowhead Pharmaceuticals recorded a trading volume of 3,584,577 shares, which was above the three months average volume of 1,143,970 shares. The stock ended the day 21.25% lower at 2.78. The share price has gained 131.67% from its 52 week low with a 52 week trading range of 1.20 - 8.09.The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $2.37 is greater than its 200-day moving average of $1.88. Shares of Arrowhead Pharmaceuticals have gained approximately 80 percent year-to-date.

Access RDI's Arrowhead Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ARWR

Our Actionable Research on Aldeyra Therapeutics Inc. (NASDAQ: ALDX) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com